Department of Frontier Life Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Division of Chemotherapy and Clinical Research, National Cancer Center Research Institute, Chuo-ku, Tokyo, Japan.
Cancer Res. 2019 Aug 1;79(15):3851-3861. doi: 10.1158/0008-5472.CAN-18-1037. Epub 2019 May 29.
Poly (ADP-ribose) glycohydrolase (PARG) is the main enzyme responsible for catabolism of poly (ADP-ribose) (PAR), synthesized by PARP. PARG dysfunction sensitizes certain cancer cells to alkylating agents and cisplatin by perturbing the DNA damage response. The gene mutations that sensitize cancer cells to PARG dysfunction-induced death remain to be identified. Here, we performed a comprehensive analysis of synthetic lethal genes using inducible PARG knockdown cells and identified dual specificity phosphatase 22 (DUSP22) as a novel synthetic lethal gene related to PARG dysfunction. DUSP22 is considered a tumor suppressor and its mutation has been frequently reported in lung, colon, and other tumors. In the absence of DNA damage, dual depletion of PARG and DUSP22 in HeLa and lung cancer A549 cells reduced survival compared with single-knockdown counterparts. Dual depletion of PARG and DUSP22 increased the apoptotic sub-G fraction and upregulated in lung cancer A549, PC14, and SBC5 cells, and inhibited the PI3K/AKT/mTOR pathway in A549 cells, suggesting that dual depletion of PARG and DUSP22 induced apoptosis by upregulating and suppressing the PI3K/AKT/mTOR pathway. Consistently, the growth of tumors derived from double knockdown A549 cells was slower compared with those derived from control siRNA-transfected cells. Taken together, these results indicate that deficiency exerts a synthetic lethal effect when combined with PARG dysfunction, suggesting that DUSP22 dysfunction could be a useful biomarker for cancer therapy using PARG inhibitors. SIGNIFICANCE: This study identified as a novel synthetic lethal gene under the condition of dysfunction and elucidated the mechanism of synthetic lethality in lung cancer cells.
多聚(ADP-核糖)水解酶(PARG)是负责降解多聚(ADP-核糖)(PAR)的主要酶,PAR 由 PARP 合成。PARG 功能障碍通过扰乱 DNA 损伤反应,使某些癌细胞对烷化剂和顺铂敏感。使癌细胞对 PARG 功能障碍诱导的死亡敏感的基因突变仍有待确定。在这里,我们使用诱导型 PARG 敲低细胞对合成致死基因进行了全面分析,并鉴定出双特异性磷酸酶 22(DUSP22)为与 PARG 功能障碍相关的新型合成致死基因。DUSP22 被认为是一种肿瘤抑制因子,其突变已在肺癌、结肠癌和其他肿瘤中频繁报道。在没有 DNA 损伤的情况下,HeLa 和肺癌 A549 细胞中 PARG 和 DUSP22 的双重敲低与单一敲低相比,细胞存活率降低。PARG 和 DUSP22 的双重敲低增加了肺癌 A549、PC14 和 SBC5 细胞中的凋亡亚 G 期分数,并上调了这些细胞中的 ,同时抑制了 A549 细胞中的 PI3K/AKT/mTOR 通路,表明 PARG 和 DUSP22 的双重敲低通过上调 和抑制 PI3K/AKT/mTOR 通路诱导细胞凋亡。一致地,与对照 siRNA 转染细胞来源的肿瘤相比,源自双重敲低 A549 细胞的肿瘤生长较慢。总之,这些结果表明,在 PARG 功能障碍的情况下, 缺陷表现出合成致死效应,表明 DUSP22 功能障碍可能是使用 PARG 抑制剂进行癌症治疗的有用生物标志物。意义:本研究鉴定出 为 PARG 功能障碍条件下的新型合成致死基因,并阐明了肺癌细胞中合成致死性的机制。